Iodine → 6-Chloro-3-[1-(1-methyl-1H-indazol-5-yl)-ethyl]-imidazo[1,2-b]pyridazine
反応式
[Cl:1][C:2]1[CH:3]=[CH:4][C:5]2[N:6]([C:8]([C:11]([C:14]3[CH:15]=[C:16]4[C:20](=[CH:21][CH:22]=3)[N:19]([CH3:23])[N:18]=[CH:17]4)(O)[CH3:12])=[CH:9][N:10]=2)[N:7]=1.II.O[PH2]=O.ClC1C=CC2N(C(CC3C=C4C(=CC=3)N(C)N=C4)=CN=2)N=1>>[Cl:1][C:2]1[CH:3]=[CH:4][C:5]2[N:6]([C:8]([CH:11]([C:14]3[CH:15]=[C:16]4[C:20](=[CH:21][CH:22]=3)[N:19]([CH3:23])[N:18]=[CH:17]4)[CH3:12])=[CH:9][N:10]=2)[N:7]=1参加物
5
反応物 4
生成物 1
実験手順
The title compound (390.0 mg, 91%) was synthesized from 1-(6-chloro-imidazo[1,2-b]pyridazin-3-yl)-1-(1-methyl-1H-indazol-5-yl)-ethanol (430.0 mg, 1.31 mmol), I2 (832.0 mg, 3.28 mmol) and H3PO2(0.72 mL, 6.56 mmol) using the same procedure as described in the synthesis of compound 13.2. 1H-NMR (400 MHz, DMSO-d6) δ ppm 8.18 (d, 1H), 7.95 (s, 1H), 7.83 (s, 1H), 7.55 (m, 2H), 7.36 (d, 1H), 7.28 (d, 1H), 4.70 (q, 1H), 3.99 (s, 3H), 1.74 (d, 3H). LCMS (method A): [MH]+=312, tR=5.49 min.
出典と根拠
- ORDレコード
- ord-eb6f202db05a4795be38be8179d74404
- 出典データセット
- uspto-grants-2013_08
- 特許番号
- US08507676B2
反応ノート
読み込み中…